Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13966248 | 0.85 | SLC6A4 (0.43) | SMN1; SMN2MAPK1HTTSLC6A4HTR2C | |
| SCHEMBL10203575 | 0.83 | MEN1 (0.36) | SLC6A4HTR2CSLC6A2SLC6A3HTR2A | |
| SCHEMBL13104119 | 0.79 | SCN8A (0.41) | SMN1; SMN2SLC6A4SCN8ASLC6A2SLC6A3 | |
| SCHEMBL10206061 | 0.78 | TAAR1 (0.41) | MAPK1SLC6A4HTR2C | |
| SCHEMBL13104123 | 0.77 | HTT (0.53) | HTTHPGDSCN8A | |
| SCHEMBL13104144 | 0.76 | ALDH1A1 (0.48) | SLC6A4HTR2CHTR2APDE2A | |
| SCHEMBL18232514 | 0.75 | DPP4 (0.35) | SMN1; SMN2MAPK1HTTSLC6A4HTR2C | |
| SCHEMBL20255348 | 0.73 | LMNA (0.36) | SMN1; SMN2MAPK1HTTSLC6A4HTR2C | |
| SCHEMBL14290420 | 0.73 | SLC6A4 (0.45) | SLC6A4HTR2CSLC6A2HTR2APDE2A | |
| SCHEMBL765046 | 0.73 | GABRA1 (0.42) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | SMN1; SMN2 4259/4885MAPK1 4523/4885HTT 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.